B A C K G R O U N D
Bell's palsy is an acute unilateral paralysis of the facial nerve first described by the Scottish surgeon Sir Charles Bell (1774 to 1842) (Petruzelli 1991) . It affects 11 to 40 people per 100,000 in the population per annum, most commonly in the age group 30 to 45 (Bateman 1992; Brandenberg 1993; Katusic 1986; Pietersen 1982; Pietersen 2002; Yanagihara 1988) . The condition presents disproportionately amongst pregnant women and people who have diabetes, influenza, a cold, or some other upper respiratory ailment. On average, every year a British general practitioner will see one or two people who have developed the condition. A UK study using the general practice research database (GPRD) showed that 36% of people were treated with oral corticosteroids and 19% were referred to hospital (Rowlands 2002) . Although most recover well, 30% of people with Bell's palsy have a poor recovery with continuing facial disfigurement, psychological difficulties and sometimes facial pain (though the presence and course of pain is unclear from current knowledge) (Morgenlander 1990) . The aetiology has yet be established but genetic, vascular, infectious and immunological causes have all been postulated (Adour 1996) . Animal studies have suggested the possibility that reactivation of herpes viruses may be responsible for demyelination (Morgan 1995; Sugita 1995) . Herpes simplex virus, has been implicated as a cause in several studies (McCormick 1972; Murakami 1996; Stjernquist-Desatnik 2006; Takasu 1992; Theil 2001) . Infection with this virus is thought to cause inflammation of the facial nerve. Treatment has commonly been based on this hypothesis. Antiviral medication is supposed to eradicate the infectious agent and corticosteroids to reduce the swelling of the facial nerve.
The previous versions of the Cochrane reviews concerning the treatment of Bell's palsy examined the effectiveness of oral prednisolone and aciclovir (Allen 2007; Salinas 2002) . These found that insufficient data exist to conclude that either or both therapies are effective. Many of the studies mentioned in these reviews but excluded from the analysis either failed to randomize participants or, when correctly randomized, were erroneously interpreted in a favourable light (May 1976; Wolf 1978) . In addition, high dose corticosteroid therapy has numerous potential side effects including peptic ulceration hypertension and confusional states. Antivi-ral therapy is expensive and should be reserved for circumstances where definite benefits are likely to be obtained. Previous recommendations suggested that aciclovir needs to be started within 48 hours, although a study of viral replication in participants with Bell's palsy suggested that the window might be extended (Abiko 2002) .
Since publication of the previous versions of the Cochrane reviews, large scale, randomized controlled trials of antivirals and corticosteroids have been published necessitating substantive updates of the reviews.
O B J E C T I V E S
The objective of the review was to determine the effectiveness of anti-herpes simplex antiviral treatments for Bell's palsy. We selected as outcome variables (i) recovery status measured by conventional validated instruments and (ii) presence of motor synkinesis or crocodile tears. A third outcome variable, adverse effects of treatment, was also collected. Other symptoms (pain, discomfort and embarrassment) have been reported as outcomes in some trials but were not considered in this review.
M E T H O D S Criteria for considering studies for this review

Types of studies
We searched for all randomized or quasi-randomized (alternate or other systematic allocation) controlled trials involving aciclovir, valaciclovir or famciclovir alone or in combination with any other therapy in the treatment of Bell's palsy.
Types of participants
We considered all trials where participants were diagnosed with unilateral facial paralysis of unknown cause, and who satisfied the authors' requirements for eligibility and inclusion.
Types of interventions
We considered all trials where treatment was undertaken with any oral antiviral licensed for the treatment of herpes simplex infections in immunocompetent participants. The list comprised aciclovir, valaciclovir, a pro-drug of aciclovir and famciclovir, a prodrug of penciclovir. We considered trials where participants received antiviral therapy versus placebo or any other treatment.
Types of outcome measures
The outcome measures have been modified since the previous review to take into account the heterogeneity of this group of studies. Where outcome measures were measured 'at six months', this has been replaced by 'at the end of the study'. Duration of studies included in this review ranges from three months to 12 months: this method allows maximum data inclusion. Incomplete recovery has been altered to include the range of definitions used by the studies included to allow maximum data capture: as opposed to the previous definition of moderate dysfunction, the term now includes participants with a lack of full function. More participants will be classified as 'incomplete recovery' by this definition. 'Adverse events attributable to antiviral treatment' has been replaced with 'adverse events': in studies where both agents are administered it is difficult to assess which agent is causing the adverse event. Similarly, even when only an antiviral is being prescribed, it is difficult to know whether a specific event should be attributed to the medication or another intercurrent cause. The level of detailed analysis of adverse events in studies did not permit such a judgement being made.
Primary outcomes
Incomplete recovery of facial function at the end of study measured using a validated rating scale.
Secondary outcomes
1. Motor synkinesis or crocodile tears at the end of the study. 2. Complete facial paralysis at the end of the study. 3. Adverse events.
Search methods for identification of studies
In this updated review, we searched the Cochrane Neuromuscular Disease Group Trials register (December 2008), MEDLINE (January 1966 to December 8 2008 , EMBASE (January 1980 to December 8 2008) and LILACS (January 1982 to December 2008 . We also reviewed the bibliographies of the identified trials, contacted trial authors and known experts in the field and contacted relevant drug companies to identify additional published or unpublished data. For MEDLINE, EMBASE and LILACS database search strategies please see Appendix 1, Appendix 2 and Appendix 3.
Data collection and analysis
All five authors scrutinised the search databases to determine papers for inclusion. At least two authors independently assessed each paper for relevance, eligibility and quality. There were no disagreements about inclusion. In the first version of this review four possible trials were identified but only two qualified for inclusion. The number of references retrieved from each source was not stated. A search at the update in April 2003 generated 49 papers in EMBASE, 22 in MEDLINE and 15 in LILACS but no new trials were identified. Our new search in 2008 identified 68 papers in EMBASE, 26 in MEDLINE and 3 in LILACS. From this search, 23 papers were selected for review of the full text and five trials were subsequently included in addition to those which were included in the previous version of the review. We considered each trial design and whether it was randomized, method of randomization to treatment, dosage of all treatment comparisons (amount, frequency, duration and route of administration), whether the trial was placebo-controlled, blinded (for treatment administrator, patient and assessment of recovery status) or unstated, and for definition of recovery status. All five authors were given a selection of papers to read, review for quality and extract data from. Each trial was assessed by at least two authors. PL completed the risk of bias table which was individually reviewed by FS and FD. All five authors agreed data extraction. Two authors (PL and FD) agreed input into Review Manager (RevMan, the programme provided by the Cochrane Collaboration). Three of the trial authors were contacted for additional information and two responded with data. A previous review author was contacted for updated information on other studies and a response was received. Assessment of bias was conducted by scoring studies using the risk of bias methods described in the 2008 version of the Cochrane Handbook.according to Cochrane methods. We calculated a weighted treatment effect using the Mantel-Haenszel method (Egger 2007) . The random effects model was used where there was marked heterogeneity between studies (Chi 2 test, P < 0.1, I
2 > 50%). The fixed-effect model was used where heterogeneity was not detected with standard statistical methods. When comparing studies which use differing symptom scores to assess outcome, we used the House-Brackman scale when available as this was the most widely used or had comparisons to other scales available. When assessing adverse events, the number of participants affected, as opposed to the number of events was used to facilitate data comparison. As in previous editions of this review, the meta-analysis outcomes have been reported for both studies which compare antivirals either with or without corticosteroids to corticosteroids and those studies which compare antivirals only to corticosteroids only. We have conducted three comparisons: antivirals versus placebo (including antivirals plus corticosteroids versus placebo plus corticosteroids and antivirals plus corticosteroids versus no treatment plus corticosteroids), antivirals versus corticosteroids and antivirals plus corticosteroids versus placebo. Sensitivity analysis has been used to assess the effects of combining trials with and without additional treatments in the analysis of antivirals verus placebo and the impact of length of follow up on the meta-analysis results.
R E S U L T S Description of studies
See: Characteristics of included studies; Characteristics of excluded studies; Characteristics of studies awaiting classification. Five randomized controlled trials with 1787 participants in total were added to the previous version of this review which had two trials and 200 participants. All five trials provided a comparison of disease outcome after antiviral treatment with disease outcome after an otherwise identical treatment regimen lacking the antiviral component. One thousand nine hundred and eighty-seven participants were included in the seven included studies. Engstrom (Engström 2008) recruited 829 participants to be treated within 72 hours of onset and randomized by a computerised mechanism in a two-stage process into four treatment groups: valaciclovir with prednisolone or valaciclovir with placebo or placebo with prednisolone or double placebo in a factorial design. The trial was blinded for administrator, patient and assessment of recovery status until the end of follow-up. Participants were assessed at onset, after two weeks (11 to 17 days), after one, two, three, six and 12 months. Disease status was measured using the House-Brackmann grading system and the Sunnybrook scale. Recovery status was defined by a Sunnybrook score of 100 and a House-Brackman grade of 1. Time to recovery was estimated. Data analysis included an assessment of treatment interaction. The study reported no effect on recovery time due to valaciclovir (P = 0.76). Recovery rates at 12 months were 57.5% in the valaciclovir group compared with 57.3% in the placebo group (P = 1.00). For this review, we aggregated the antiviral plus corticosteroid with the antiviral plus placebo group and the corticosteroid plus placebo with the double placebo group to achieve the most powerful comparison for the effect of treatment with valaciclovir on recovery rates at 12 months. We analysed these recovery rates 12 months after palsy onset from their results. With complete recovery defined as a Sunnybrook score of 100, 271 out of 413 recovered with valaciclovir compared with 266 out of 416 recovered without valaciclovir, RR 1.03. With complete recovery defined as a House-Brackmann grade of I, 297 out of 413 recovered with valaciclovir compared with 293 out of 416 without valaciclovir, RR 1.02. Hato (Hato 2007) randomized 296 participants within seven days of onset using sealed envelopes into two treatment groups: valaciclovir with prednisolone or placebo with prednisolone. Two hundred and twenty-one participants were included in the final anal-ysis. The administrators were not blinded to the treatment allocation but the participants were blinded to treatment received. Those assessing recovery status were not blinded to treatment. Participants' disease severity was assessed using the Yanagihara scale and were assessed as completely recovered if attaining a score greater than 36. Participants were assessed at onset and monthly thereafter for six months or until completely recovered if recovery occurred before six months. The group reported significant benefit from treatment with antivirals and corticosteroids compared to corticosteroids alone: recovery in the group receiving valaciclovir and prednisolone was seen in 110/114 and recovery in the placebo and prednisolone group was seen in 96/107, RR 1.08 at six months after palsy onset. Kawaguchi (Kawaguchi 2007) recruited 150 participants to be treated within seven days of onset and randomized using sealed envelopes into two treatment groups: valaciclovir with prednisolone or prednisolone alone. Thus we deduce that there was no blinding for administrator or participant. Participants were assessed at onset using both the Yanagihara 40-point scale and House-Brackmann index. Recovery was measured using only the Yanagihara index (36 or more). Recovery time in days was recorded. Follow up was scheduled for one week, two weeks and one, two, three, four, five and six months. This trial reported no significant difference in recovery rate between the prednisolone group and the prednisolone-aciclovir group at six months. Sullivan (Sullivan 2007 ) recruited 551 participants to be treated within 72 hours of onset and randomized by a dedicated remote telephone-computerised mechanism in a two-stage process into four treatment groups: aciclovir with prednisolone (AS) or aciclovir with placebo (AO) or placebo with prednisolone (OS) or double placebo (OO) in a factorial design. The trial was blinded for administrator, participant and assessment of recovery status until the end of follow-up. Participants were assessed at onset, after three months, and if still unwell at three months, after nine months. Recovery status was measured using the House-Brackmann scale with complete recovery defined by House-Brackmann grade I. Data analysis included an assessment of treatment interaction. Sullivan (Sullivan 2007) reported final outcomes on 496 completed participants at three months and nine months and shows a beneficial effect of not receiving antivirals. The nine month recovery rates were 211 out of 247 in the aciclovir group compared with 226 out of 249 among participants not receiving aciclovir, RR 0.92. Yeo (Yeo 2008) recruited 91 participants with Bell's palsy who were randomized to receive either aciclovir and prednisolone or prednisolone alone. All participants also received physical therapy and plasma volume expanders as adjuncts. The trial was double blind and participants were followed up for six months or until complete recovery. Recovery was assessed using the House-Brackmann scale and defined as a House-Brackmann score of 2 or less.
Yeo (Yeo 2008) reported outcomes for 91 participants at two and six months. There was no significant difference in recovery between the two treatment groups. The six month recovery rate in the antivirals and corticosteroids group was 44 out of 44 and in the corticosteroids only group 40 out of 47, RR 1.17. Details of other studies previously included in this review are given below. Adour (Adour 1996) recruited 119 participants of whom 99 were included in the published analysis. The study was double-blind and placebo-controlled. Participants were recruited within three or less days since the onset of paralysis and received either aciclovir and prednisolone or placebo and prednisolone. The study duration was four months and participants were reviewed at two weeks, two months and four months. This was a single centre study. The Facial Paralysis Recovery Index (FPRI) was used to measure facial function and the primary trial outcome was incomplete recovery defined by a FPRI 7 or less. This study reported significant benefit of treatment with aciclovir plus corticosteroids compared with corticosteroids alone, RR 1.22 after four months. De Diego (De Diego 1998) recruited 113 participants and included 101 in the final analyses. Participants were randomly assigned treatment: blinding status was not clear. Evaluation was carried out within 48 hours of the onset of symptoms and participants received either aciclovir for 10 days or prednisolone for 16 days (reducing dose). Reviews were scheduled for one, three, six and 12 weeks after initial contact with further contact if persistent incomplete recovery was noted. The primary study outcome was recovery as defined using the House-Brackmann and facial paralysis recovery profile scales. Full recovery was defined as a HouseBrackman score of 2 or less or a Facial Paralysis Recovery Profile (FPRP) of 8 or more. The final length of follow-up is not reported but stated as 'until complete recovery or stabilization of the paralysis'. This study reported significant treatment benefit in the corticosteroids only group, RR 0.83. We have changed the status of the Antunes (Antunes 2000) study for this report from 'included' to 'excluded'. The authors of the previous edition of this review initially included it but found the data to be incomplete and, despite attempting to contact the authors, there was not sufficient information for the data to be usefully included in the analyses. We have reassessed the inclusion of the two studies awaiting assessment (P de Aquino 2001; Roy 2005) . The author of the previous version of this review, Dr. D. Allen, tried to contact the author of the former paper for clarification of the data, but this has not been forthcoming and so we have excluded this trial because of a lack of adequate information. The latter study appeared as an abstract in a journal supplement and has not, according to the search strategies employed, been published as a full paper. Again, this trial has been excluded due to a lack of adequate information. A further study awaits classification (Inanli 2001) .This was in-cluded in a recently published systematic review and meta-analysis (Goudakos 2009). We await translation and interpretation. Updated status of this paper will be included in the next update of the Cochrane Review.
Risk of bias in included studies
The risk of bias is summarised in Figure 1 . 
Sequence generation, allocation concealment and blinding
Three studies (Adour 1996; Engström 2008; Sullivan 2007) were randomized, double-blind and placebo-controlled to minimise the effects of bias. Kawaguchi (Kawaguchi 2007) described a randomized study but states that the treatment was revealed to the clinician and the absence of a placebo made treatment clear to the recipient. The remaining two studies (De Diego 1998; Hato 2007) all described randomization but not blinding or placebo use. Yeo (Yeo 2008) stated that their study was randomized and doubleblind: this was not described within the text and so this study has been graded as unclear for these attributes. 
Incomplete outcome data
Selective outcome reporting
All studies, except Adour 1996 reported all their intended primary outcomes. Adour failed to report on audiometry and stapedial reflex testing. Engström 2008 reported all primary outcomes and stated that secondary outcomes will be reported in a later paper. (House 1985) and Engstrom supplemented this using the Sunnybrook scale (Ross 1996) to minimise the effects of interrater variability.
Other potential sources of bias
Statistical analysis
Six out of the seven studies analysed gave adequate detail: they clearly stated and then used appropriate statistical tests. Only Hato (Hato 2007) scored unclear in this category as the tests used were not stated.
Differences in baseline between groups
Six out of the seven trials were adequate in this category. De Diego (De Diego 1998) found a significant difference in rates of hypertension between the two groups: further analysis revealed that there was no significant difference in trial outcomes as a result. Kawaguchi (Kawaguchi 2007) reported a significant difference between mean age of the treatment groups but further analysis of the age distribution using the Chi 2 test revealed no significant difference. In the tables in the other studies, no significant differences between the baseline groups were reported.
Effects of interventions
As all trials reported different intervals and lengths of follow up lengths, the analyses were performed on data reported at the end of the study periods of three months (De Diego 1998) 
Antivirals versus placebo (including antivirals plus corticosteroids versus placebo plus corticosteroids and antivirals plus corticosteroids versus no treatment plus corticosteroids)
This comparison contained six studies (Adour 1996; Engström 2008; Hato 2007; Kawaguchi 2007; Sullivan 2007 and Yeo 2008) with 1886 participants in total. The relative rate of incomplete recovery at the end of the study did not show a significant difference between treatment with antiviral and treatment with placebo, the RR of incomplete recovery being 0.88 (95% CI 0.65 to 1.18), Analysis 1.1 and Figure 2 . Heterogeneity was high when the fixed-effect model was used (Chi 2 = 11.78, P 0.04, I 2 58%), the random-effects model was used to partially correct for this. We analysed two subgroups of these trials. 
Antivirals versus corticosteroids
This comparison contained three studies (De Diego 1998; Engström 2008 and Sullivan 2007) with 768 participants in total. All three studies gave data for our primary outcome, recovery at the end of the study. Incomplete recovery was significantly less common in the participants treated with antivirals than those treated with corticosteroids. Initial calculations using the fixedeffect model showed RR 1.96 (95% CI 1.48 to 2.59) but with a high degree of heterogeneity (Chi 2 8.78, P = 0.01, I 2 77%). The analysis was repeated using the random-effects model to partially correct for this, Analysis 2.1 and Figure 3 , RR 2.82 (95% CI 1.09 to 7.32). 
Antivirals plus corticosteroids versus placebo
This comparison contained two studies (Engström 2008; Sullivan 2007) and outcome data on 658 participants. Incomplete recovery at the end of the study was significantly much less common with the combined treatment than placebo, Analysis 3.1 and Figure 4 , RR 0.56 (95% CI 0.41, 0.76). This analysis had low heterogeneity (Chi 2 0.14, P 0.71, I 2 0%). There were no data available for motor synkinesis or crocodile tears at the end of the studies. Adverse events were slightly but not significantly more common with combined treatment than with placebo, RR 1.15 (95% CI 0.79 to 1.66), Analysis 3.2.
Sensitivity analyses
We investigated the effects of using the comparison antivirals plus corticosteroids, placebo or no treatment versus corticosteroids, placebo or no treatment by performing further analyses to investigate whether our conclusions were altered when studies with a follow-up of less than six months were excluded (De Diego 1998 and Adour 1996) and when only outcomes reported at greater than six months were included (Engström 2008 and Sullivan 2007 ). This represents no significant change seen with the removal of outcomes which reported follow up at six months or less. When sensitivity analysis was performed to assess the differing response to aciclovir and valaciclovir, no significant difference was found. Overall the RR for aciclovir was 0.93 (95% CI 0.45 to 1.90, n = 686) in an analysis which included data from three trials. Overall the RR for valaciclovir was 0.87 (95% CI 0.66 to 1.14, n = 1200) in an analysis including data from three trials.
Antivirals versus corticosteroids
When the De Diego 1998 study was excluded and the analysis was just performed with Engström 2008 and Sullivan 2007, the relative risk of more benefit with antivirals than with corticosteroids, for the outcome incomplete recovery at the end of the study, was no longer significant, RR 2.69 (95% CI 0.73 to 10.01, n = 667).This study differed in reporting outcome at less than six months and its exclusion changed the conclusion of the meta-analysis from "significant" to "non-significant". Sensitivity analysis assessing the differing response to aciclovir versus valaciclovir did not alter the overall conclusion from the metaanalysis. The respective results were RR aciclovir 4.68 (95% CI 2.25 to 9.74, n = 351) with data from two trials and valaciclovir RR 1.50 (95% CI 1.11 to 2.03, n = 417) with data from one trial.
Antiviral plus corticosteroid versus placebo
There was no change in the data for this analysis, based on Engström 2008 and Sullivan 2007. This represents no significant effect from excluding studies, which report the outcome incomplete recovery at the end of the study, which report at less than 6 months. Sensitivity analysis looking at aciclovir and valaciclovir both resulted in a change to these results. For aciclovir, with data from one trial, the RR was 0.49 (95% CI 0.23 to 1.05, n = 246) and for valaciclovir, again with data from one trial, the RR was 0.58 (95% CI 0.41 to 0.80, n = 412). In both cases, this represents a loss of significance in the difference between outcomes for antivirals plus corticosteroids versus placebo.
D I S C U S S I O N
This updated review resolves much of the uncertainty about the value of herpes simplex antivirals for Bell's palsy. There was no evidence of significant benefit from antivirals in comparison with placebo but they were significantly less efficacious than corticosteroids.
When antivirals were compared to placebo, there was little difference in the recovery of participants receiving either treatment RR 0.88 (95% CI 0.65 to 1.18). This result was influenced by the Sullivan 2007 trial which suggested that antiviral treatment had a non-significant detrimental effect on recovery: 27 out of 123 participants receiving antivirals had incomplete recovery compared to 18 out of 122 participants receiving placebo, RR 1.48 (95% CI 0.87 to 2.56). A possible reason is that, although active against the presumed infective agent, antiviral medication causes increased local inflammation and exacerbation of symptoms (Jarisch-Herxheimer reaction).
When antiviral treatment was compared to corticosteroid treatment, the participants receiving corticosteroid treatment were significantly more likely to recover than those receiving antiviral treatment: that is, there was more incomplete recovery in the antiviral group RR 2.82 (95%CI 1.09 to 7.32). This analysis displayed significant heterogeneity which was not fully corrected by applying the random-effects model and needs to be interpreted with caution.
Similarly, the outcome was significantly better in the participants receiving corticosteroid and antiviral treatment compared with placebo: that is the RR of incomplete recovery was significantly less, 0.56 (95% CI 0.41 to 0.76), in those who received combined treatment.
The RR of incomplete recovery, calculated using the fixed-effects model, was significantly less 0.75 (95% CI 0.57 to 0.98) with the combined treatment than with corticosteroids alone which would suggest a beneficial effect from antivirals but this analysis showed moderate heterogeneity and should be interpreted with caution.
The source of heterogeneity may be due to clinical variation for example in study participant characteristics, disease severity at baseline, delay in receiving treatment or type of antiviral agent used. Equally, variation may be due to methodological considerations such as method of randomization, the use of blinding, the choice of outcome assessment measures and recovery cut-off points or the trial duration. In particular, Hato 2007 and Kawaguchi 2007 had methodological weaknesses in baseline group assessment, completeness of follow-up and adequate blinding. Any of these factors could result in bias and introduce inaccuracy.The heterogeneity was exacerbated by keeping the inclusion criteria fairly broad: this maximises data inclusion and therefore power, but results must be interpreted with this in mind.
Sensitivity analysis of trials with data with less than a six month end-point showed results similar to those achieved with the whole group analysis -no significant effect of shortened time of follow up was detected.
Similarly, sub-group analysis of the relative treatment difference with different antivirals showed no significant change in the antivirals versus placebo or antivirals versus corticosteroids results.
In the antivirals plus corticosteroids comparison, the examination of individual therapy removed the significant difference in incomplete outcome. Given this, it is unlikely that different antivirals, despite the difference in bio-availability (Sullivan 2007), will have a significant affect on the outcome of incomplete recovery at the end of the study.
Given that a significant benefit in terms of incomplete recovery at end of study was derived from the combination of antivirals plus corticosteroids, this may merit further investigation. It may be that the use of prednisolone suppresses the Jarish-Harxheimer reaction and allows the antiviral treatment to provide some benefit.
There were insufficient data to examine any other variables which are reported in the studies, such as pain, quality of life and variation in response due to time to treatment and severity at onset. These variables can be used as hypothesis generation for future work in this area.
From the minimal data available for comparison of motor synkinesis or crocodile tears at the end of the study, the results of two studies with separate comparisons with a total number of participants of 200 were not significant. De Diego (De Diego 1998) compared antivirals with corticosteroids and found fewer episodes of these outcomes in the corticosteroids group while Adour (Adour 1996) compared antivirals and corticosteroids with corticosteroids and found fewer episodes of these outcomes in the antiviral treatment group. Relatively low participant numbers and a degree of clinical (different clinical assessment scales used) and methodological heterogeneity (different treatment regimes and follow up plans) limit the interpretation of these data.
No data were available in any of the studies to assess the outcome 'complete paralysis at the end of the study'.
Adverse events data were available in three studies (Engström 2008; Hato 2007 and Sullivan 2007) giving comparison data on 1544 participants. None of the comparisons showed significant differences in adverse events between either arm . No correlation with specific treatment could be found within these results. Studies conducted in Asia, North America and Europe, have been included. It is possible that genetic differences in drug metabolism or response or even different aetiological processes may account some of the variation in response which is observed.
The other important consideration which is raised by the primary outcome result are the health economic issues: a 10 day course of aciclovir 400 mg five times daily costs GBP 9.28; valaciclovir and famciclovir equivalent courses cost significantly more; a 10 day course of prednisolone (two 25 mg tablets daily), costs about GBP 7.14 (BNF 2008). These cost data are specific to the current UK market and costs vary significantly in other countries (Hernández 2008).
Further work in this area could address the questions raised by the possible causes of heterogeneity in some of the comparisons in this review and may be achieved through a combination of epidemiological work and further large randomized controlled trials which collect comparable data for sub-group analysis and metaregression.
A U T H O R S ' C O N C L U S I O N S Implications for practice
High quality evidence from randomized controlled trials of herpes simplex antivirals for the treatment of Bell's palsy showed no significant benefit from antivirals compared to placebo. High quality evidence showed significant benefit from the combination of antivirals and corticosteroids compared with placebo. Moderate quality evidence showed significantly less benefit from antivirals than corticosteroids. There was no significant increase in adverse events from antivirals compared with either placebo or corticosteroids.
Implications for research
The results cast doubt on previous hypotheses suggesting herpes simplex as the cause of Bell's palsy and research should be aimed at discovering alternative causes.
More work is needed to assess the likelihood of long term cosmetic sequelae. Sub-group analysis of existing data and future studies should be done to assess the impact of variables such as time from diagnosis until treatment received, severity of palsy at baseline and age of patient at presentation on the outcome. Work assessing softer end-points such as quality of life and perceived disability should be done to develop better understanding of Bell's palsy at the patient level.
A C K N O W L E D G E M E N T S
Dr J Sipe, Mrs L Dunn and Dr D Allen authored the previous editions of this review and we are very grateful for their hard work and enthusiasm. Furthermore, Dr D Allen communicated with Dr P Lockhart and assisted with clarification of the status of some studies. Our thanks are also extended to the Cochrane Neuromuscular Disease Group for their extensive technical assistance and support. 
R E F E R E N C E S
References to studies included in this review
C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of included studies [ordered by study ID]
Adour 1996
Methods Double-blind. Placebo-controlled. 
Hato 2007
Methods Random allocation to 2 groups to receive either valaciclovir and prednisolone (VP) or placebo and prednisolone (PP). Using the 'envelope' method Participants 296 participants randomized; 152 participants to VP, 144 participants to PP. All participants commenced treatment within 7 days of onset of palsy. All participants over 15 years and had no contraindications to antivirals or corticosteroids. 221 patients were included in the final analysis Interventions Randomized to receive prednisolone 60 mg for 5 days, 30 mg for 3 days and 10 mg for 2 days +/-valaciclovir 1000 mg/ day for 5 days. All participants received mecobalamin 1500 micrograms per day following corticosteroids for 6 months or until complete recovery Outcomes Primary outcome full recovery based on a score of >= 36 on the Yanagihara scale Follow up at 1,3 and 6 months after commencing treatment.
Final outcomes reported at 6 months.
Notes
Multi-centre: 6 academic tertiary referral centres. Measurements using Yanagihara scale -conversion scale to House-Brackmann scale included in paper
Risk of bias
Item
Authors' judgement Description
Adequate sequence generation? Yes Quote "the patients were randomly divided into two groups using the envelope method" 
Kawaguchi 2007
Methods Random allocation to receive either prednisolone or prednisolone and valaciclovir. Using the 'envelope' method Participants 150 participants: 66 prednisolone, 84 prednisolone and valaciclovir. All participants received treatment within 7 days from onset of palsy. All participants aged 15 or older and had no contraindications to corticosteroids or antivirals Interventions Participants received 20 mg three times daily for days 1 to 5, then 10 mg three times daily days 6 to 8, then 10 mg daily days 9 and 10 +/-valaciclovir 500 mg twice a day for 5 days Outcomes Facial movement and recovery measured using the Yanagihara scale where compete recovery was taken as a score of >= 36 Virological examination for presence of antiHSV and VZV antibodies and detection of HSV and VZV reactivation. Frequency of incomplete recovery at end of study and adverse events recorded but not published -information obtained from author (by PL) Follow up for 6 months at 1 and 2 weeks after treatment and then at 1, 2, 3, 4, 5 and 6 months after treatment Final outcomes reported at 6 months.
Notes Multi-centre: 12 university hospitals. Yanagihara rating scale 
Risk of bias
Sullivan 2007
Methods Double-blind, placebo-controlled randomized, factorial trial. Participants allocated to one of four treatment groups to receive either aciclovir, prednisolone, both agents or placebo Participants 551 participants randomized and 496 included in final outcomes assessment. Referred for assessment and treatment within 72 hours of paralysis onset. All participants aged 16 or older and no contraindications to corticosteroids or antivirals Interventions Participants received prednisolone 25 mg twice daily for 10 days or aciclovir 400 mg five times daily for 10 days, both or neither depending upon allocation Outcomes Primary outcome measure was recovery rated on House-Brackmann scale where recovery was a score of H-B grade 1 Secondary outcomes included health-related quality of life, Health Utilities Index Mark 3, facial appearance (Derriford appearance scale) pain and adverse outcomes. Frequency of incomplete recovery at end of study was recorded Follow up at 3 and 9 months. Final outcomes reported at 9 months. Notes Multi-centre: 17 hospitals. House-Brackmann Scale.
Risk of bias
Item
Authors' judgement Description
Adequate sequence generation? Yes Quote "...patient was randomly assigned to a study group by an independent, secure, automated telephone randomization service.."
Allocation concealment? Yes All parties blinded to allocation. 
A D D I T I O N A L T A B L E S
C O N T R I B U T I O N S O F A U T H O R S
All authors contributed to the review and data extraction process. Dr F Daly wrote the first draft of the report with all clinical inputs from Professor F Sullivan and Dr P Lockhart. Dr P Lockhart incorporated the work into the existing review and was responsible for risk of bias assessment, data analysis and use of the RevMan software.
D E C L A R A T I O N S O F I N T E R E S T
Dr F Daly and Professor F Sullivan are named authors on one of the included studies (Sullivan 2007).
S O U R C E S O F S U P P O R T
Internal sources
• University of Dundee, UK.
External sources
• No sources of support supplied
D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
There are several differences between the published review protocol and this version of the review. These mainly reflect the changes over time to the treatment options and Cochrane methodology. The search for studies now includes treatment with valaciclovir and famciclovir, either alone or in combination with any other therapy, to reflect the treatment options now available for Bell's palsy. The methodological assessment has been undertaken according to the latest Cochrane guidance, detailed in the Cochrane Handbook for Systematic Reviews of Interventions Chapter 8. Criteria for judging study quality are sequence generation, allocation concealment, blinding of participants and outcome assessors, selective outcome reporting and other sources of bias. The criteria are assessed as 'Yes', indicating a low likelihood of bias, 'No', indicating a high likelihood of bias or 'Unclear' where information is not sufficient to make a judgement. Other sources of bias which are considered includes diagnostic criteria, outcome criteria, baseline differences between groups and completeness of follow up. All five authors were given a selection of papers to read, review for quality and extract data from. The work was distributed so that each paper was reviewed by at least two authors. PL performed the final risk of bias quality assessment procedure which was independently reviewed by FS and FD.
We have focused this search on immunocompetent patients, which was not stipulated in the original protocol. This has been done as treatment protocols for immunocompromised individuals and treatment response may differ significantly from other individuals and, as such, cannot be fully explored in this analysis.
